drugset / Trial / NCT05798689

Use of a Selected Mixture of Probiotic Strains for Degrading Gluten During Digestion

NCT05798689 ↗

RandomizedParallel-groupTriple-blindScreening

Summary

Gluten intake spreads worldwide, being the major food protein consumed in the Western diets (up to 20 g gluten/d). But gluten has unique and unusual features. It resists the complete luminal digestion by gastric, pancreatic and intestinal brush border enzymes, and is susceptible to post-translational modification (deamidation) by mucosal transglutaminases. Apart from partial digestion, gluten per se has a negative impact on a consistent part of the worldwide population, which mainly results in the manifestations of celiac disease (CD) or other gluten-related disorders. This study will enable to test in vivo a novel multi-species probiotic that in vitro has proven to degrade gluten to non-immunotoxic peptides.

Timeline

Start
2020-10-01
Primary completion
2021-04-30
Completion
2021-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Probiotic preparation Unknown — —

Indications

No indication recorded.